Umbilical cord-derived mesenchymal stem cells for hematopoietic stem cell transplantation

Yu Hua Chao; Han Ping Wu; Chin Kan Chan; Chris Tsai; Ching Tien Peng; Kang Hsi Wu

doi:10.1155/2012/759503

Umbilical cord-derived mesenchymal stem cells for hematopoietic stem cell transplantation

Yu Hua Chao, Han Ping Wu, Chin Kan Chan, Chris Tsai, Ching Tien Peng, Kang Hsi Wu^*

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

31 Scopus citations

Abstract

Hematopoietic stem cell transplantation (HSCT) is becoming an effective therapeutic modality for a variety of diseases. Mesenchymal stem cells (MSCs) can be used to enhance hematopoietic engraftment, accelerate lymphocyte recovery, reduce the risk of graft failure, prevent and treat graft-versus-host disease, and repair tissue damage in patients receiving HSCT. Till now, most MSCs for human clinical application have been derived from bone marrow. However, acquiring bone-marrow-derived MSCs involves an invasive procedure. Umbilical cord is rich with MSCs. Compared to bone-marrow-derived MSCs, umbilical cord-derived MSCs (UCMSCs) are easier to obtain without harm to the donor and can proliferate faster. No severe adverse effects were noted in our previous clinical application of UCMSCs in HSCT. Accordingly, application of UCMSCs in humans appears to be feasible and safe. Further studies are warranted.

Original language	English
Article number	759503
Journal	Journal of Biomedicine and Biotechnology
Volume	2012
DOIs	https://doi.org/10.1155/2012/759503
State	Published - 2012
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1155/2012/759503

Cite this

@article{35141978df0648a894e4b072b5548040,

title = "Umbilical cord-derived mesenchymal stem cells for hematopoietic stem cell transplantation",

abstract = "Hematopoietic stem cell transplantation (HSCT) is becoming an effective therapeutic modality for a variety of diseases. Mesenchymal stem cells (MSCs) can be used to enhance hematopoietic engraftment, accelerate lymphocyte recovery, reduce the risk of graft failure, prevent and treat graft-versus-host disease, and repair tissue damage in patients receiving HSCT. Till now, most MSCs for human clinical application have been derived from bone marrow. However, acquiring bone-marrow-derived MSCs involves an invasive procedure. Umbilical cord is rich with MSCs. Compared to bone-marrow-derived MSCs, umbilical cord-derived MSCs (UCMSCs) are easier to obtain without harm to the donor and can proliferate faster. No severe adverse effects were noted in our previous clinical application of UCMSCs in HSCT. Accordingly, application of UCMSCs in humans appears to be feasible and safe. Further studies are warranted.",

author = "Chao, {Yu Hua} and Wu, {Han Ping} and Chan, {Chin Kan} and Chris Tsai and Peng, {Ching Tien} and Wu, {Kang Hsi}",

year = "2012",

doi = "10.1155/2012/759503",

language = "英语",

volume = "2012",

journal = "Journal of Biomedicine and Biotechnology",

issn = "1110-7243",

publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Umbilical cord-derived mesenchymal stem cells for hematopoietic stem cell transplantation

AU - Chao, Yu Hua

AU - Wu, Han Ping

AU - Chan, Chin Kan

AU - Tsai, Chris

AU - Peng, Ching Tien

AU - Wu, Kang Hsi

PY - 2012

Y1 - 2012

N2 - Hematopoietic stem cell transplantation (HSCT) is becoming an effective therapeutic modality for a variety of diseases. Mesenchymal stem cells (MSCs) can be used to enhance hematopoietic engraftment, accelerate lymphocyte recovery, reduce the risk of graft failure, prevent and treat graft-versus-host disease, and repair tissue damage in patients receiving HSCT. Till now, most MSCs for human clinical application have been derived from bone marrow. However, acquiring bone-marrow-derived MSCs involves an invasive procedure. Umbilical cord is rich with MSCs. Compared to bone-marrow-derived MSCs, umbilical cord-derived MSCs (UCMSCs) are easier to obtain without harm to the donor and can proliferate faster. No severe adverse effects were noted in our previous clinical application of UCMSCs in HSCT. Accordingly, application of UCMSCs in humans appears to be feasible and safe. Further studies are warranted.

AB - Hematopoietic stem cell transplantation (HSCT) is becoming an effective therapeutic modality for a variety of diseases. Mesenchymal stem cells (MSCs) can be used to enhance hematopoietic engraftment, accelerate lymphocyte recovery, reduce the risk of graft failure, prevent and treat graft-versus-host disease, and repair tissue damage in patients receiving HSCT. Till now, most MSCs for human clinical application have been derived from bone marrow. However, acquiring bone-marrow-derived MSCs involves an invasive procedure. Umbilical cord is rich with MSCs. Compared to bone-marrow-derived MSCs, umbilical cord-derived MSCs (UCMSCs) are easier to obtain without harm to the donor and can proliferate faster. No severe adverse effects were noted in our previous clinical application of UCMSCs in HSCT. Accordingly, application of UCMSCs in humans appears to be feasible and safe. Further studies are warranted.

UR - http://www.scopus.com/inward/record.url?scp=84871844339&partnerID=8YFLogxK

U2 - 10.1155/2012/759503

DO - 10.1155/2012/759503

M3 - 文献综述

C2 - 23093863

AN - SCOPUS:84871844339

SN - 1110-7243

VL - 2012

JO - Journal of Biomedicine and Biotechnology

JF - Journal of Biomedicine and Biotechnology

M1 - 759503

ER -

Umbilical cord-derived mesenchymal stem cells for hematopoietic stem cell transplantation

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this